Replies to post #87584 on Biotech Values

[DewDiligence]

ACHN re: Viral rebound

“…maintaining a mean reduction of more than 2.0 log10 from baseline through day 12, the last day of viral load measurement in the study.”

We need to be careful here: the above statement refers only to the mean of the patient cohort—it is not the same as saying that all patients in the cohort maintained a viral-load drop of at least 2 logs relative to baseline.

Moreover, the metric of most interest in assessing viral rebound is not the change relative to baseline but rather the change relative to the trough.

All told, the ACHN data reported today are clearly positive, but there’s a lot of relevant information that hasn’t yet been disclosed.

[DewDiligence]

will try and make this my last ACHN-related post of the night as I don't want to clutter up the board with ACHN-related posts.

Don’t worry about it—readers who are not interested in ACHN can simply skip those posts.

Q: Has ACHN disclosed how many cohorts the phase-1b portion of the trial will have?